Gene and epigenetic editing in the treatment of primary ciliopathies

Area of Science:

• Genetics
• Molecular Biology
• Ophthalmology
• Nephrology

Background:

• Primary ciliopathies are severe inherited disorders caused by mutations in ciliary genes, affecting multiple organs like the kidney and eye.
• Current treatments for ciliopathies are limited, highlighting the need for novel therapeutic strategies.
• Gene editing tools, particularly CRISPR/Cas systems, show potential for correcting causative genetic mutations in these disorders.

Purpose of the Study:

• To explore the potential and challenges of CRISPR/Cas-based gene editing therapies for primary ciliopathies.
• To evaluate the feasibility of in situ gene correction for renal and retinal ciliopathies.
• To discuss the current status and future directions for CRISPR/Cas applications in treating ciliopathies.

Main Methods:

• Review of CRISPR/Cas systems as gene editing tools for genetic disorders.
• Analysis of the eye as a target for in vivo gene correction due to accessibility and compartmentalization.
• Discussion of technological requirements for developing in vivo CRISPR-based treatments for kidney ciliopathies.

Main Results:

• CRISPR/Cas systems are versatile and effective gene editing tools with clinical potential.
• The eye is a suitable target for in vivo gene correction therapies, with clinical studies already underway for retinal ciliopathies.
• Systemic delivery and specificity remain challenges for CRISPR/Cas therapies, particularly for kidney applications.

Conclusions:

• CRISPR/Cas-based gene editing holds significant promise for treating primary ciliopathies.
• The eye presents a more accessible target for current in vivo gene correction strategies compared to the kidney.
• Further technological advancements are necessary to fully realize the potential of CRISPR/Cas therapies for renal ciliopathies.